Bristol Myers Squibb Company $BMY Holdings Boosted by Sequoia Financial Advisors LLC

Posted by Brian Himes on Sep 11th, 2026

Sequoia Financial Advisors LLC grew its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 6.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 179,874 shares of the biopharmaceutical company’s stock after purchasing an additional 11,558 shares during the period. Sequoia Financial Advisors LLC’s holdings in Bristol Myers Squibb were worth $10,364,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of BMY. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the fourth quarter valued at $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth about $25,000. Davis Asset Management L.P. acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth about $27,000. Bayban purchased a new position in Bristol Myers Squibb during the 4th quarter valued at about $31,000. Finally, Addison Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Positive Phase 2 results for arlo-cel in heavily pretreated multiple myeloma strengthen Bristol Myers Squibb’s cell-therapy pipeline and could support future growth if the treatment advances successfully. Bristol Myers Squibb Reports Positive Phase 2 Results for Arlo-cel
Positive Sentiment: An update from a long-term psoriasis study provides additional data for investors evaluating Sotyktu and Bristol Myers Squibb’s ability to expand its growth-brand portfolio. Bristol Myers Squibb’s Long-Term Psoriasis Study
Positive Sentiment: Analysts continue to cite momentum from BMY’s growth brands and pipeline progress. Sector concerns following safety issues in a Novartis CAR-T program may also improve the relative appeal of Bristol Myers Squibb’s cell-therapy efforts, although this is not a direct change to BMY’s fundamentals. Could Bristol-Myers Squibb Outperform Novartis?
Neutral Sentiment: Scotiabank maintained its Hold rating, suggesting the current valuation and outlook do not yet justify a stronger bullish view. Scotiabank Keeps Its Hold Rating
Neutral Sentiment: Recent coverage focused on BMY’s market underperformance rather than a new fundamental announcement, indicating investor caution after the stock’s recent weakness. Bristol Myers Squibb Declines More Than Market
Negative Sentiment: Unusually heavy put-option activity—44,454 contracts, approximately 71% above typical volume—signals increased near-term hedging or bearish speculation, though options activity alone does not confirm a fundamental deterioration.
Negative Sentiment: RBC said Cytokinetics has an advantage in a patent dispute involving Bristol Myers Squibb, creating potential legal and competitive risk for BMY. Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute
Negative Sentiment: Generic pressure on BMY’s legacy portfolio remains a key concern, potentially offsetting growth-brand gains and limiting enthusiasm for the shares.

Bristol Myers Squibb Stock Down 1.0%

Shares of Bristol Myers Squibb stock opened at $63.76 on Friday. The firm has a market cap of $130.25 billion, a price-to-earnings ratio of 14.04, a P/E/G ratio of 0.31 and a beta of 0.23. The stock has a 50-day simple moving average of $63.50 and a 200-day simple moving average of $60.05. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm’s revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Insider Buying and Selling

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts recently commented on BMY shares. Royal Bank Of Canada raised their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Wells Fargo & Company set a $65.00 target price on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 target price for the company in a research note on Wednesday, August 5th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $66.33.

View Our Latest Stock Report on BMY

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.